Bolus/infusional 5-fluorouracil and folinic acid. A report on two prospective, consecutive phase II studies with 5-fluorouracil dose escalation
1998

Study of 5-Fluorouracil and Folinic Acid in Colorectal Cancer

Sample size: 192 publication Evidence: moderate

Author Information

Author(s): MJ Mackean, J Cassidy, D Jodrell, J Paul, NS Reed, PA Canney, H Yosef, T Habeshaw, AG Robertson, A McInnes, CJ Twelves

Primary Institution: Beatson Oncology Centre, Glasgow, UK

Hypothesis

Increasing the dose of 5-fluorouracil will improve response rates in patients with advanced colorectal carcinoma.

Conclusion

The study found a low response rate of 18% and a median survival of 7.8 months in patients treated with 5-fluorouracil and folinic acid.

Supporting Evidence

  • The overall response rate was 18% with a complete response of 6% and partial response of 12%.
  • Overall median survival was 34 weeks with no significant difference between the two cohorts.
  • Poor performance status and elevated initial WBC were associated with reduced survival.

Takeaway

Doctors tested a medicine to help people with a type of cancer, but not many got better, and most lived for about 8 months.

Methodology

The study used a group sequential design to evaluate two dose levels of 5-fluorouracil and folinic acid in patients with advanced colorectal carcinoma.

Potential Biases

The cohorts were not randomized, which may introduce selection bias.

Limitations

The study was not randomized and had a relatively low response rate.

Participant Demographics

Patients had advanced colorectal cancer, with a median age of 63 years and similar demographic features across cohorts.

Statistical Information

P-Value

0.27

Confidence Interval

95% CI 30-39 weeks

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication